Clinical Trial

Evolut PRO China Clinical Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-07-28; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting 2023-02-22
Status change: Not Yet Recruiting → Recruiting 2021-09-01
Trial Details
NCT Number NCT04982588
Lead Sponsor Medtronic Cardiovascular
Conditions Severe, Symptomatic Aortic Stenosis
Enrollment 52 participants
Start Date 2021-07-17
Primary Completion 2023-03-17 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-03